[
    [
        {
            "time": "2021-08-16",
            "original_text": "超100家基金公司分别调研海康威视、迈为股份、长春高新",
            "features": {
                "keywords": [
                    "长春高新",
                    "调研",
                    "基金公司"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "超100家基金公司分别调研海康威视、迈为股份、长春高新",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "长春高新：将围绕基因工程药物、生物疫苗等五大板块布局",
            "features": {
                "keywords": [
                    "长春高新",
                    "基因工程",
                    "生物疫苗",
                    "布局"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "长春高新：将围绕基因工程药物、生物疫苗等五大板块布局",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "长春高新：预计短期内生长激素产品不会进入国家集采",
            "features": {
                "keywords": [
                    "长春高新",
                    "生长激素",
                    "国家集采"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "长春高新：预计短期内生长激素产品不会进入国家集采",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "太平洋维持长春高新买入评级：生长激素高景气，盈利能力稳定提升",
            "features": {
                "keywords": [
                    "长春高新",
                    "买入评级",
                    "生长激素",
                    "盈利能力"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "太平洋维持长春高新买入评级：生长激素高景气，盈利能力稳定提升",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "光大证券：维持长春高新(000661.SZ)“买入”评级 百克生物登陆科创板 利于疫苗业务长远发展",
            "features": {
                "keywords": [
                    "长春高新",
                    "买入评级",
                    "百克生物",
                    "疫苗业务"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "光大证券：维持长春高新(000661.SZ)“买入”评级 百克生物登陆科创板 利于疫苗业务长远发展",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "国金证券维持长春高新买入评级，业绩超预期，盈利能力持续优化",
            "features": {
                "keywords": [
                    "长春高新",
                    "买入评级",
                    "业绩超预期",
                    "盈利能力"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券维持长春高新买入评级，业绩超预期，盈利能力持续优化",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "中航证券给予长春高新买入评级，2021半年报点评，近期获8份券商研报关注，目标均价涨幅63.42%",
            "features": {
                "keywords": [
                    "长春高新",
                    "买入评级",
                    "半年报",
                    "目标涨幅"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中航证券给予长春高新买入评级，2021半年报点评，近期获8份券商研报关注，目标均价涨幅63.42%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "兴业证券：予长春高新(000661.SZ)“增持”评级 中报业绩符合预期 金赛延续高增长",
            "features": {
                "keywords": [
                    "长春高新",
                    "增持评级",
                    "中报业绩",
                    "金赛高增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "兴业证券：予长春高新(000661.SZ)“增持”评级 中报业绩符合预期 金赛延续高增长",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "西南证券维持长春高新买入评级：业绩高速增长，生长激素持续放量",
            "features": {
                "keywords": [
                    "长春高新",
                    "买入评级",
                    "业绩高速增长",
                    "生长激素"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券维持长春高新买入评级：业绩高速增长，生长激素持续放量",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "8月15日33只个股获券商关注，长春高新目标涨幅达65.18%",
            "features": {
                "keywords": [
                    "长春高新",
                    "券商关注",
                    "目标涨幅"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "8月15日33只个股获券商关注，长春高新目标涨幅达65.18%",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]